With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...

One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...

TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...